KemPharm, Inc. announced that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", US Patent No. 7,772,222. This patent protects broad aspects of the company's core Ligand Activated Therapy (LAT) prodrug ... KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm's proprietary Ligand Activated Therapy (LAT) prodrug approach. The pharmacokinetic (PK) profile of d ... KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm’s proprietary Ligand Activated Therapy (LAT) prodrug approach. NORTH LIBERTY, Iowa----KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder . KP106, a new chemical entity composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm’s proprietary Ligand Activated Therapy prodrug approach.